BCAS3 Accelerates Glioblastoma Tumorigenesis by Restraining the P53/GADD45α Signaling Pathway.
Yixuan Wang,Yuntao Li,Qian Sun,Fanen Yuan,Yang Xu,Shiao Tong,Yong Li,Shangfeng Yi,Tengfeng Yan,Qianxue Chen,Baohui Liu
DOI: https://doi.org/10.1016/j.yexcr.2022.113231
IF: 4.145
2022-01-01
Experimental Cell Research
Abstract:As in many other cancers, highly malignant proliferation and disordered cell division play irreplaceable roles in the exceedingly easy recurrence and complex progression of glioblastoma multiforme (GBM); however, mechanistic studies of the numerous regulators involved in this process are still insufficiently thorough. The role of BCAS3 has been studied in other cancers, but its role in GBM is unclear. Here, our goal was to investigate the expression pattern of BCAS3 in GBM and its potential mechanism of action. Using TCGA database and human GBM samples, we found that BCAS3 expression was up-regulated in GBM, and its high expression predicted poor prognosis. To further investigate the relationship between BCAS3 and GBM characteristics, we up-regulated and down-regulated BCAS3 expression in GBM to detect its effect on cell proliferation and cell cycle. At the same time, we established U87 cells stably overexpressing BCAS3 and generated an intracranial xenograft model to investigate the Potential role of BCAS3 in vivo. Finally, based on in vitro cell experiments and in vivo GBM xenograft models, we observed that BCAS3 significantly regulates GBM cell proliferation and cell cycle and that this regulation is associated with p53/GADD45 alpha Signaling pathway. Taken together, our findings suggest that BCAS3 is inextricably linked to the progression of GBM and that targeting BCAS3 may have therapeutic effects in GBM patients.
What problem does this paper attempt to address?